Moberg Pharma (MOB.ST) Stock Analysis & AI Equity Report
Moberg Pharma (MOB.ST) overview
Moberg Pharma (MOB.ST) stock analysis and AI equity research. For the latest completed financial year, 2025, Moberg Pharma reported revenue of SEK 13.5m and operating profit of SEK -28.0m; the year-end share price was 10.27 SEK and market capitalisation was SEK 481m. Moberg Pharma is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Moberg Pharma's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2026-05-11. Data will be refreshed during report generation.
About Moberg Pharma
Moberg Pharma AB is a Swedish specialty pharmaceutical company focused on commercializing proprietary medicines based on proven substances. Its main product is MOB-015, a topical treatment for nail fungus sold as Terclara in Sweden and Norway and partnered in other markets. The company’s value driver is expanding this dermatology portfolio through direct sales and commercial partnerships.
Generate the Moberg Pharma report
Moberg Pharma is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Moberg Pharma and represent the latest completed financial year (2025). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.